IFNA2 and cholangiocarcinoma: Similarly, clinical trials have been conducted in CCA patients to evaluate the efficacy of interferon-alpha 2 with an immune checkpoint blockade pembrolizumab (Clinicaltrials.gov identifier NCT02982720), or in combination with standard-of-care chemotherapy (Clinicaltrials.gov identifier NCT00019474).